Theodora Pappa1, Jesper Johannesen2, Neal Scherberg1, Maricel Torrent3, Alexandra Dumitrescu1, Samuel Refetoff1,4. 1. 1 Department of Medicine, The University of Chicago , Chicago, Illinois. 2. 2 Paediatric Department at Copenhagen University Hospital , Herlev, Denmark . 3. 3 Department of Molecular Modeling, Discovery, Research and Development, AbbVie, North Chicago, Illinois. 4. 4 Department of Pediatrics and the Committee on Genetics, The University of Chicago , Chicago, Illinois.
Abstract
BACKGROUND: Thyrotropin (TSH) deficiency caused by TSHβ gene mutations is a rare form of congenital central hypothyroidism. Nine different TSHβ gene mutations have been reported, all with clinical manifestations. The aim was to identify the genetic cause of undetectable TSH levels in two siblings with clinical euthyroidism. METHODS: Two brothers born to consanguineous Pakistani parents presented with undetectable serum TSH but normal iodothyronine concentrations and no clinical signs of hypothyroidism. Direct sequencing of the TSHβ gene, functional and immunological studies, protein homology modeling, and population frequency analysis were performed to characterize the cause of undetectable TSH in this family. RESULTS: Direct sequencing of the TSHβ gene revealed that the two brothers were homozygous for a single nucleotide substitution (c.223A>G) resulting in the replacement of arginine 55 with glycine (R55G). This variant was found in 12 out of 5008 alleles in the 1000 Genomes project (all South Asian). Serum TSH of the two brothers was undetectable in two of five platforms, both produced by Siemens, whereas TSH levels of the heterozygous brother and mother were half compared to the other three platforms (Roche Elecsys, Abbott Architect, and Beckman Coulter DxI). The falsely low TSH concentration was caused by the monoclonal antibody not recognizing the region containing the variant amino acid. This is supported by the fact that arginine modification--following phenylglyoxal treatment--led to a significant (96%) decrease in the TSH measurement with the Siemens platforms. Predictions based on PolyPhen-2 and in silico modeling revealed no functional impairment of the variant TSH. CONCLUSIONS: A TSHβ variant with impaired immunoreactivity, but not bioactivity, is reported, and its biochemical impact in the homo- and heterozygous state is demonstrated. It is also shown that failure to bind to the monoclonal antibody is a direct consequence of the amino acid substitution.
BACKGROUND: Thyrotropin (TSH) deficiency caused by TSHβ gene mutations is a rare form of congenital central hypothyroidism. Nine different TSHβ gene mutations have been reported, all with clinical manifestations. The aim was to identify the genetic cause of undetectable TSH levels in two siblings with clinical euthyroidism. METHODS: Two brothers born to consanguineous Pakistani parents presented with undetectable serum TSH but normal iodothyronine concentrations and no clinical signs of hypothyroidism. Direct sequencing of the TSHβ gene, functional and immunological studies, protein homology modeling, and population frequency analysis were performed to characterize the cause of undetectable TSH in this family. RESULTS: Direct sequencing of the TSHβ gene revealed that the two brothers were homozygous for a single nucleotide substitution (c.223A>G) resulting in the replacement of arginine 55 with glycine (R55G). This variant was found in 12 out of 5008 alleles in the 1000 Genomes project (all South Asian). Serum TSH of the two brothers was undetectable in two of five platforms, both produced by Siemens, whereas TSH levels of the heterozygous brother and mother were half compared to the other three platforms (Roche Elecsys, Abbott Architect, and Beckman Coulter DxI). The falsely low TSH concentration was caused by the monoclonal antibody not recognizing the region containing the variant amino acid. This is supported by the fact that arginine modification--following phenylglyoxal treatment--led to a significant (96%) decrease in the TSH measurement with the Siemens platforms. Predictions based on PolyPhen-2 and in silico modeling revealed no functional impairment of the variant TSH. CONCLUSIONS: A TSHβ variant with impaired immunoreactivity, but not bioactivity, is reported, and its biochemical impact in the homo- and heterozygous state is demonstrated. It is also shown that failure to bind to the monoclonal antibody is a direct consequence of the amino acid substitution.
Authors: Julia C Drees; Judith A Stone; C Randy Reamer; Victoria E Arboleda; Karl Huang; Jane Hrynkow; Dina N Greene; Matthew S Petrie; Carolyn Hoke; Thomas S Lorey; Richard S Dlott Journal: J Clin Endocrinol Metab Date: 2013-01-01 Impact factor: 5.958
Authors: G Medeiros-Neto; D T Herodotou; S Rajan; S Kommareddi; L de Lacerda; R Sandrini; M C Boguszewski; A N Hollenberg; S Radovick; F E Wondisford Journal: J Clin Invest Date: 1996-03-01 Impact factor: 14.808
Authors: Reham S Ebrhim; Ryan J Bruellman; Yui Watanabe; Matthew K Creech; Mohamed A Abdullah; Alexandra M Dumitrescu; Samuel Refetoff; Roy E Weiss Journal: Horm Res Paediatr Date: 2020-01-08 Impact factor: 2.852